Univercells Technologies, acquired in June 2023 by Donaldson, says that the Gene Therapy Program at the University of Pennsylvania (GTP) is expanding its evaluation agreement aimed at determining the scalability of GTP’s gene therapy product manufacturing using Univercells Technologies’ bioreactors.
GTP is an academic program led by James M. Wilson, MD, PhD, and focused on genetic medicines. Wilson serves as the Rose H. Weiss Professor and Director of the Orphan Disease Center and a professor of medicine and pediatrics at the Perelman School of Medicine.
GTP seeks to make gene therapies for rare diseases accessible worldwide. This agreement covers GTP’s evaluation of the commercial-series scale-X™ nitro 600 m2 bioreactor, with the goal of substantially increasing production per batch and potentially reducing cost of goods sold (COGS).
“We are honored to extend our collaborative work with GTP in evaluating the scalability of gene therapy production,” said Mathias Garny, general manager at Univercells Technologies.
“Our mission aligns closely with GTP’s vision of making gene therapies more accessible globally, and we are committed to supporting their efforts with our innovative bioprocessing technologies.”
Univercells Technologies developed the scale-X bioreactor with the support of the Bill and Melinda Gates Foundation’s Global Grand Challenge initiative. Originally designed to lower the cost of viral vaccine production for critical public health vaccines, the scale-X bioreactor is now being applied to enable viral vector accessibility for gene therapies.
![Univercells Technologies’ scale-X™ nitro 200 m2 and the scale-X nitro 600 m2, which is the instrument covered under the agreement between Univercells Technologies and the University of Pennsylvania Gene Therapy Program. [Univercells Technologies] Univercells Technologies’ scale-X™ nitro 200 m2 and the scale-X nitro 600 m2, which is the instrument covered under the agreement between Univercells Technologies and the University of Pennsylvania Gene Therapy Program. [Univercells Technologies]](https://static.packgene.com/wp-content/uploads/2024/07/scale-X-nitro-200-600-w-logo-696x348-1.png)
Univercells Technologies’ scale-X™ nitro 200 m2 and the scale-X nitro 600 m2, which is the instrument covered under the agreement between Univercells Technologies and the University of Pennsylvania Gene Therapy Program. [Univercells Technologies]
“Our hope is that Univercells Technologies will improve the efficiency of AAV vector manufacturing and help play a role in decreasing costs and enabling access through more affordable prices in the future,” said Wilson.
https://www.genengnews.com/topics/bioprocessing/univercells-technologies-and-upenn-expand-gene-therapy-partnership/

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
